Presentation by Quin Wills, CSO, Ochre-Bio, UK

Humans as the model: human fatty liver perfusion to bypass poorly predictive animal models

Share this article:

Soving NASH and chronic liver disease requires better use of human data

Ochre Bio was founded around a simple concept – that to solve NASH and chronic liver disease requires better use of human data. That means more human data in discovery, more human data in validation, and better clinical trials. We’ll walk through Ochre’s human-only liver pipeline, from large-scale sequencing of human livers in Asia, Europe, and the US through to testing lead assets in perfused human livers.